News, Stat Consult
This review provides a concise overview of the incidence, risk factors, pathogenesis, diagnostic criteria, differential diagnosis, and treatment of gastroparesis.
OVERVIEW: What every practitioner needs to know Are you sure your patient has Multiple Sclerosis? What are the typical findings for this disease? A first attack of neurological symptoms in children with central nervous system (CNS) demyelination may represent a monophasic illness or be the first presentation of a chronic relapsing disorder such as multiple…
At a Glance MS is considered in the presence of clinically objective neurologic deficits and evidence of past events of neurologic symptoms (e.g., in the patient history). The neurologic symptoms themselves are notoriously variable and can come in virtually any form. Typical symptoms include paresthesia, weakness, ataxia, dysarthria, sensory deficits, and impaired or double vision.…
Preliminary Diagnosis: Multiple Sclerosis I. What imaging technique is first-line for this diagnosis? Contrasted MR of the brain per demyelinating protocol Contrasted MR of the cervical spine may additionally be performed to search for any cervical spine demyelinating plaques. II. Describe the advantages and disadvantages of this technique for diagnosis of multiple sclerosis. Advantages Highly…
News, Stat Consult
This review provides a concise overview of the types, pathogenesis, diagnostic criteria, differential diagnosis, and treatment of multiple sclerosis.
Pediatrics Information Center
Gilenya is the first multiple sclerosis drug approved for children
Neurology Information Center
The FDA approved Ocrevus to treat adults with primary progressive multiple sclerosis and relapsing forms of the disease.
Dimethyl fumarate is the third oral medication available to treat multiple sclerosis.
Patients with multiple sclerosis who had high levels of sodium intake were 3.4 times more likely to develop a new lesion.
Level 3: Lacking direct evidence Dalfampridine (Ampyra) extended release tablets, previously called Fampridine-SR, have been approved by the FDA to improve walking in patients with multiple sclerosis. In two clinical trials with 507 patients, the drug was associated with consistent improvement in walking speed on a 25-foot walk when compared with placebo (NNT 4). However,…